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Abstract
Background: The presence of concomitant Type II diabetic mellitus (T2DM) and
depressive symptoms adversely affects individuals with symptomatic heart fail-
ure (HF).
Hypothesis: In presymptomatic stage B HF, this study hypothesized the presence of
greater inflammation and depressive symptoms in T2DM as compared to non-T2DM
Stage B patients.
Methods: This cross-sectional study examined clinical parameters, inflammatory bio-
markers, and depressive symptoms in 349 T2DM and non-T2DM men with asymp-
tomatic stage B HF (mean age 66.4 years ±10.1; range 30-91).
Results: Fewer diabetic HF patients had left ventricular (LV) systolic dysfunction
(P < .05) although more had LV diastolic dysfunction (P < .001). A higher percentage of
T2DM HF patients were taking ACE-inhibitors, beta-blockers, calcium channel
blockers, statins, and diuretics (P values < .05). T2DM HF patients had higher circulat-
ing levels of interleukin-6 (IL-6) (P < .01), tumor necrosis factor-alpha (P < .01), and sol-
uble ST2 (sST2) (P < .01) and reported more somatic/affective depressive symptoms
(Beck Depression Inventory II) (P < .05) but not cognitive/affective depressive symp-
toms (P = .20). Among all patients, in a multiple regression analysis predicting presence
of somatic/affective depressive symptoms, sST2 (P = .026), IL-6 (P = .010), B-type
natriuretic peptide (P = .016), and sleep (Pittsburgh Sleep Quality Index [P < .001])
were significant predictors (overall model F = 15.39, P < .001, adjusted R2 = .207).
Conclusions: Somatic/affective but not cognitive/affective depressive symptoms are
elevated in asymptomatic HF patients with T2DM patients. Linkages with elevated
inflammatory and cardiac relevant biomarkers suggest shared pathophysiological
mechanisms among T2DM HF patients with somatic depression, and these condi-
tions are responsive to routine interventions, including behavioral. Copyright © 2019
John Wiley & Sons, Ltd.
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1 | INTRODUCTION
The American College of Cardiology/American Heart Association
(ACC/AHA) heart failure (HF) staging system denotes four unique
stages that emphasize both the evolution and the progression of
chronic HF. One of the major goals of the system is to identify individ-
uals at early stages of the disease with the hope that early implemen-
tation of therapeutic interventions might ultimately reduce morbidity
and mortality.1 Stage B consists of patients who have developed
structural or functional changes but who have never shown signs or
symptoms of HF (eg, previous myocardial infarction, asymptomatic
valvular disease, left ventricular hypertrophy, reduced ejection frac-
tion). Progression from asymptomatic stage B to symptomatic stage C
HF is associated with a 5-fold increase in premature mortality risk.2
Like HF, Type II diabetic mellitus (T2DM) is a significant health
problem, with rates expected to increase an estimated 25% over the
next 7 years.3 T2DM is a significant comorbidity because, along with
hypertension and obesity, it represents an independent risk factor for
the development of HF.4,5 Like HF, T2DM is associated with chronic
inflammation.6 Among symptomatic HF patients, presence of T2DM
predicts morbidity and mortality.7
Major depression is common in cardiovascular diseases and asso-
ciated with poor medical outcomes.7 In symptomatic HF, studies have
substantiated linkages between depression and inflammatory pro-
cesses.8,9 In T2DM, a history of depression is associated with a higher
rate of microvascular complications and higher HbA1c.10 Depression
in T2DM independently and incrementally predicts incident HF.11
In addition to major depression, depressive symptoms are also ele-
vated in both HF8,12 and in T2DM.13 Screening for depression symp-
toms can be routinely accomplished using standardized
questionnaires such as the Beck Depression Inventory II (BDI-II).14
Several studies underscore the importance of differentiating the type
of depressive symptoms the patient has, whether more som-
atic/affective or cognitive/affective depressive symptoms. For exam-
ple, de Miranda Azevedo et al showed that in cardiovascular disease
patients it is the somatic/affective depressive symptoms but not the
cognitive/affective depressive symptoms that are related to poorer
outcomes.15 Similarly, Delisle et al showed that following myocardial
infarction the somatic/affective depressive symptoms contributed
more to overall depression than the cognitive/affective depressive
symptoms.16 We previously showed in symptomatic HF patients that
a behavioral treatment for depressive symptoms was more successful
in reducing somatic/affective rather than cognitive/affective depres-
sive symptoms, which have been linked to worse prognosis in HF.17
In contrast to the above research among patients with symptom-
atic HF (stage C), few studies have examined the comorbidity of
depressive symptoms and T2DM in presymptomatic stage B HF. This
paper sought to examine these relationships, and, in accordance with
the studies described above which highlight the importance of differ-
entiating somatic/affective vs cognitive/affective symptoms,16-18
examine potential clinical and inflammatory predictors of these phe-
nomena in asymptomatic HF with and without T2DM.
2 | METHODS
Participants were 18 years or older with clinically stable AHA/ACC
classification stage B HF with a diagnosis for at least 3 months. The
sample consisted of 349 men. Patients were recruited from the Uni-
versity of California, San Diego (UCSD) Medical Center and the Vet-
erans Affairs San Diego Healthcare System (VASDHS) Cardiology
clinics. Individuals with a current cancer diagnosis or immune-related
disorders including chronic infectious diseases (eg, HIV, hepatitis) and
autoimmune and inflammatory disorders (eg, rheumatoid arthritis,
multiple sclerosis, lupus, SLE, gout, sarcoidosis) were excluded, as
were individuals with a body mass index (BMI) greater than
40, because of the known effects of these conditions on inflammatory
biomarkers. The study was approved by the VASDHS and UCSD
Human Subjects Institutional Review Boards. Written informed con-
sent was obtained from all study participants.
Based on recommendations and cut-points from the American
Society of Echocardiography guidelines, the presence of stage B HF
was defined as structural or functional heart disease.19 Measurements
were made by sonographers blinded to patient characteristics.20 Left
ventricular ejection fraction (%LVEF) was assessed by echocardiogra-
phy as part of the patient's routine medical evaluation. Medication
usage was obtained from the medical record. T2DM was deemed pre-
sent when diagnosed by the research participant's primary care physi-
cian via medical record abstraction. Upon presentation to the
laboratory, a nonfasting blood draw was obtained using a 21- or
23-gauge butterfly needle. Patients performed a 6-minute walk test
to assess functional capacity.21
2.1 | Depressive symptom severity
The 21-item BDI-II assesses depressive symptoms, but does not pro-
vide a diagnosis of Major Depressive Disorder (MDD).22 BDI-II scores
≥13 indicate possible clinical depression (or at least minimal depres-
sive symptomatology, or presence of depressive symptomatology.) If
suspected of having actual clinical depression, patients were pres-
ented with a list of mental health treatment options, and their treating
physician was notified. Approximately 20% of the cohort were taking
antidepressants, which included tricyclic antidepressants, tetracyclic
antidepressants, selective serotonin reuptake inhibitors, atypical anti-
psychotics, and selective serotonin and norepinephrine reuptake
inhibitors. This study did not assess for presence of MDD but rather
depressive symptoms only. The BDI provides a total score for depres-
sive symptoms and two sub-scores: one, somatic/affective symptoms,
and the other, cognitive/affective symptoms.17 As noted in the Intro-
duction, prior studies demonstrate the value of differentiating som-
atic/affective vs cognitive/affective depressive symptoms in cardiac
patients.15-17 BDI cognitive symptoms of depression include sadness,
guilt, suicidality, and self-criticism. BDI somatic symptoms of depres-
sion include tiredness or fatigue, loss of interest, and changes in sleep,
sex drive, and weight.
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2.2 | Sleep quality
The Pittsburgh Sleep Quality Index (PSQI) was used to independently
assess sleep.23 Sleep quality is often disrupted in HF and associated
with depressive symptoms, and common symptoms of somatic
depression include poor sleep.24 The PSQI is widely used in sleep
research and measures sleep disturbance and usual sleep habits. Its
TABLE 1 Patient characteristics according to group (mean ± SD or percentage value)
T2DM (n = 116) Non-T2DM (n = 233) P values
Age (years) 66.34 (8.33) 66.45 (10.8) .921
Body mass index (kg/m2) 32.1 (6.8) 29.2 (4.9) .000
Percent overweight (BMI ≥25 to ≤29.9) 25.8 37.3 .044
Percent obese (BMI ≥ 30) 63.7 40.8 .000
Waist-hip ratio 0.995 (0.065) 0.962 (0.062) .001
Race (%) .296
Asian 8.9 3.0
African-American 14.2 11.7
Native Hawaiian/Pacific Islander <1 1.7
Caucasian 71.5 79.4
Native-American <1 <1
More than one race 3.6 2.6
Ethnicity (%) .019
Latino 12.5 4.4
Non-Latino 86.7 92.5
Unknown/declined <1 3.1
Systolic blood pressure (mm Hg) 132.4 (18.5) 132.6 (17.1) .935
Diastolic blood pressure (mm Hg) 74.1 (12.8) 76.4 (11.9) .300
Percent hypertension (≥140/90 mm Hg) 36.2 32.1 .437
Heart rate (bpm) 68.3 (12.9) 64.0 (11.9) <0.01
Left ventricular ejection fraction (%) 65.0 (7.76) 64.4 (9.47) .437
Percent patients with LV systolic dysfunction 3.4 5.5 <0.05
Percent patients with LV diastolic dysfunction 79 68 .001
Six-minute walk test (m) 1029.3 (298) 1124.6 (302) <0.02
Etiology: percent previous MI 5.2 7.2 .331
Etiology: percent hypertension 83.6 54.4 .012
Medications (% of patients using)
ACE-blocking agents 51.8 37.9 .017
ARBs 17.5 11.0 .096
Beta blockers 57.7 43.9 .019
Calcium channel blockers 30.2 19.9 .037
Statin 75.2 55.0 .001
Aspirin 54.6 39.9 .012
Diuretics 31.4 20.3 .027
Warfarin 13.3 14.0 .822
Digoxin 3.6 1.8 .316
Antidepressants 20.2 19.4 .711
Sleep (PSQI total score) 8.075 (4.20) 7.296 (4.09) .112
BDI total 9.21 (7.64) 7.83 (6.91) .068
BDI cognitive 4.88 (5.55) 4.09 (4.94) .179
BDI somatic 4.55 (2.89) 3.82 (2.77) .039
Abbreviations: ACE, Angiotensin converting enzyme inhibitors; ARB, Angiotensin II receptor blockers; BDI, Beck Depression Inventory; BMI, body mass
index; LV, left ventricular; PSQI, Pittsburgh Sleep Quality Index; T2DM, Type II diabetic mellitus.
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internal reliability and construct validity are high, correlating well with
measures of sleep quality and sleep problems.25
2.3 | Biomarkers
Considering linkages between inflammation and depressed mood in
HF,8,9,26 we used commercial assays to assess the inflammatory bio-
markers interleukin-6 (IL-6) and tumor necrosis factor-R1 (TNF-R1)
(MSD, Rockville, Maryland). We also assessed C-reactive protein
(MSD, Rockville, Maryland) and cardiac biomarkers B-type natriuretic
peptide (BNP) immunoassay (Bayer, Tarrytown, New York) and solu-
ble ST2 (sST2) (R&D Systems, Inc., Minneapolis, Minnesota). Whole
blood was preserved with EDTA acid. Following centrifugation the
plasma was stored at −80C until assay. Intra- and inter-assay coeffi-
cients were <7%).
2.4 | Data analysis
Analytic approaches included chi-square, analysis of variance, and
multiple linear regression. All tests were two-tailed. Prior to statistical
analyses, data were tested for normality and homogeneity of variance
using the Kolmogorov-Smirnov and Shapiro-Wilk normality tests.
Results were considered statistically significant at the P < .05 level.
Analyses were performed using SPSS (version 24.0) software pack-
ages (IBM, Armonk, New York).
3 | RESULTS
Table 1 presents the study variables according to T2DM diagnosis or
non-T2DM. Overall, 116 of the 339 patients (34%) had T2DM. By
definition, these patients had higher fasting glucose (P < .001) and
HbA1c (P < .001) levels than non-T2DM patients. Twenty-two per-
cent of diabetics were on insulin therapy. T2DM patients had higher
BMI (P < .001), greater waist-hip ratio (P < .001), higher resting heart
rate (P < .01), and a shorter 6-minute walk test (P < .02). More T2DM
patients were obese (BMI ≥ 30.0) (P < .001) and overweight (BMI ≥25
to ≤29.9) (P < .05). LV diastolic dysfunction was more common in the
T2DM patients (P < .001) while systolic dysfunction was less common
(P < .05). Percent EF did not vary according to T2DM diagno-
sis (P = .622).
A higher percentage of T2DM patients were taking Angiotensin
converting enzyme inhibitors (ACE)-inhibitors (P < .02), beta-blockers
(P < .02), calcium channel blockers (P < .05), statins (P < .001), aspirin
(P < .02), and diuretics (P < .02). T2DM patients had higher circulating
levels of IL-6 (P < .01), TNF-R1 (P < .01), and sST2 (P < .01). BNP levels
were not statistically significantly different according to group (Table 2).
T2DM patients reported more somatic/affective depressive symp-
toms (P < .04), but not cognitive depression symptoms (P = .179) nor
total depressive symptoms (P = .068). Thirty-nine percent of T2DM
patients scored ≥13 on the BDI vs 29% of non-T2DM patients
(P = .067). Approximately 20.2% of T2DM patients reported taking
antidepressants vs 19.4% of non-T2DM patients (P = .87).
Given that T2DM patients reported more somatic/affective
depressive symptoms, but not cognitive depression symptoms, a mul-
tiple regression analysis predicting somatic/affective symptoms was
conducted across all patients with BDI-II somatic/affective scores as
the dependent variable and relevant independent predictor variables
entered in separate blocks as shown in Table 3. The significant out-
come predictors included sST2 (P = .026), IL-6 (P = .010), BNP
(P = .016), and sleep (P < .001) (model significance P < .001; adjusted
R2 = .207) (Table 3).
4 | DISCUSSION
This study examined clinical, inflammatory, and depressive symptom
characteristics in asymptomatic stage B HF patients with and without
T2DM. T2DM stage B patients had more obesity and hypertension,
and a greater incidence of LV diastolic dysfunction, which has been
TABLE 2 Biomarkers according to group (mean ± SD)
T2DM
(n = 116)
Non-T2DM
(n = 233) P values
Glucose (mg/dL) 141.2 (57) 99.6 (17.6) .001
HbA1C (%) 6.77 (1.34) 5.58 (0.38) .001
CRP (mg/L) 6.61 (11.9) 4.98 (7.64) .097
IL-6 (pg/mL) 2.63 (2.38) 2.03 (1.79) .009
TNF-R1 (pg/mL) 1388.6 (793) 1173.2 (549) .007
sST2 (ng/mL) 19.02 (8.30) 16.88 (7.89) .204
BNP (pg/mL) 65.4 (91.7) 60.7 (67.0) .554
Abbreviations: BNP, B-type natriuretic peptide; CRP, C-reactive protein;
IL-6, interleukin-6; sST2, soluble ST2; T2DM, Type II diabetic mellitus;
TNF-R1, tumor necrosis factor-R1.
TABLE 3 Regression analysis
Dependent variable: somatic/affective depressive symptoms
Block 1: age, BMI, and T2DM diagnosis
Block 2: race, ethnicity
Block 3: systolic dysfunction, diastolic dysfunction, LVEF
Block 4: medications (as listed in Table 1)
Block 5: sleep
Block 6: biomarkers CRP, IL-6, TNF-R1, sST2, and BNP
Significant outcome predictors included:
sST2 (β = .045; P = .026)
IL-6 (β = .223; P = .010)
BNP (β = .005; P = .016)
Sleep (β = .267; P < .001)
Overall model: P < .001, adjusted R2 = 0.207
Abbreviations: BMI, body mass index; BNP, B-type natriuretic peptide;
CRP, C-reactive protein; IL-6, interleukin-6; LVEF, left ventricular ejection
fraction; sST2, soluble ST2; T2DM, Type II diabetic mellitus; TNF-R1,
tumor necrosis factor-R1.
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previously observed in stage A HF patients and is associated with
poorer prognosis.27 T2DM patients also had higher circulating levels
of IL-6, TNF-R1, and sST2, of which IL-6 and sST2 were found to be
predictors of somatic/affective depression, which was also elevated in
the T2DM patients. While we did not have the ability to fully charac-
terize the presence of metabolic syndrome, given the relatively high
percentage of diabetes, hypertension, and obesity in this cohort, it is
likely that a large percentage of the patients had metabolic
syndrome.28
In T2DM, the comorbidity of depressive symptoms and of major
depression is associated with poorer clinical management and poorer
outcomes than either alone29; the same pattern is found for coinci-
dent depression and HF.7 We found that T2DM patients specifically
had more somatic/affective depressive symptoms but not cognitive
depression symptoms nor total depressive symptoms. Som-
atic/affective depressive symptoms include fatigue, loss of interest,
and changes in sleep. Prior studies on depression in T2DM have not
differentiated between somatic/affective vs cognitive/affective symp-
toms.10,30 Studies in non-T2DM populations, however, that have dif-
ferentiated somatic/affective from cognitive/affective depression
have found this assessment approach to be beneficial.15-17 Hwang
et al reported that worsening somatic/affective depressive symptoms
but not cognitive/affective symptoms are independently associated
with increased mortality of HF patients. Such findings suggest that
routine and ongoing assessment of somatic/affective depressive
symptoms in HF patients may help clinicians identify patients at
increased risk for adverse outcomes.31 Relevant to asymptomatic
stage B patients, following myocardial infarction, somatic/affective
depressive symptoms contribute more to overall depression than the
cognitive/affective depressive symptoms.16
Mechanistically, we found that sST2, IL-6, BNP, and poor sleep
quality were independent predictors of somatic/affective depression
while BMI, type of cardiac dysfunction, and medications were not.
Regarding IL-6, there is a large literature on the role of inflammatory
processes in depression, including in HF, which point to neurohor-
monal and cytokine activation mechanisms linking these com-
orbidities.8,10,32 There is also a large literature on inflammation and
fatigue that is relevant to these findings of increased somatic depres-
sive symptoms.33
Limitations of this observational study include the demographics
of mostly white older men, thus limiting potential generalizability. In
addition, we did not assess for presence of major depression, but
rather we focused on depressive symptoms which have been shown
in the literature to be highly predictive of poor clinical course.7
It is important to note that a significant percentage of these
patients had depressive symptoms: 39% of the T2DM patients and
29% of the non-T2DM patients. As noted above, depressive symp-
toms and depressed mood are significant predictors of morbidity and
mortality in cardiac and noncardiac populations.7 Therapeutic lifestyle
changes that target diet and exercise are known to positively influ-
ence depressed mood.34,35 We have previously shown that standard
cardiac rehabilitation is effective in not only reducing mortality risk
but also in reducing depression symptoms in HF,7 and that other
forms of behavioral interventions favorably affect the som-
atic/affective but not the cognitive/affective depressive symptoms.17
Given the elevated IL-6, TNF-R1, and sST2 levels in stage B HF
patients with both T2DM and depressed mood, additional attention
and interventions to forestall potential transition to symptomatic
stage C HF may be warranted.36 The pathophysiology of stage B HF,
combined with the presence of T2DM, might synergize to advance
the likelihood of poorer outcomes. In addition to depressed mood,
stress is a known link between depression and inflammation and met-
abolic syndrome and could in part account for our observations.33,37
Studies on approaches to stress reduction have also been shown to
be helpful in improving depressed mood and inflammation.38
Going forward, considering these findings, additional attention to
assess depressive symptoms and presence of T2DM in stage B HF is
warranted. Assessing depressive symptoms in the clinic using ques-
tionnaires such as the BDI or the Hospital Anxiety and Depression
scale is relatively easy and low-cost and can provide insight into clini-
cal outcomes.39,40
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